BioCore is pushing for a crucial change in Medicare payment policies, arguing that their innovative liquid biopsy and MRD tests deserve recognition for their complex workflows.
Click to read more!
#US #CitizenPortal #MedicarePolicy #BioCoreOncology #HealthcareInnovation #GenomicSequencing
Click to read more!
#US #CitizenPortal #MedicarePolicy #BioCoreOncology #HealthcareInnovation #GenomicSequencing
BioCore urges crosswalks for plasma liquid biopsy and MRD assays, citing distinct workflow complexity
BioCore recommended crosswalking a plasma-focused liquid biopsy (0562U) to a more complex comparator and sought gap-fill for whole-genome-based MRD assays (0646U/0647U), arguing the assays’ WGS workflows and variant classes are not reflected in prior CMS crosswalks.
citizenportal.ai
July 11, 2026 at 4:44 AM
BioCore is pushing for a crucial change in Medicare payment policies, arguing that their innovative liquid biopsy and MRD tests deserve recognition for their complex workflows.
Click to read more!
#US #CitizenPortal #MedicarePolicy #BioCoreOncology #HealthcareInnovation #GenomicSequencing
Click to read more!
#US #CitizenPortal #MedicarePolicy #BioCoreOncology #HealthcareInnovation #GenomicSequencing